Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 19/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986580 | 1.00 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986349 | 1.00 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL16203432 | 0.99 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986377 | 0.99 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986594 | 0.99 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986573 | 0.95 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986469 | 0.93 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986599 | 0.92 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986466 | 0.92 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL20875230 | 0.92 | PRKCI (1.00) | PRKCIPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | claimed |
| WO-2023223519-A1 | METHOD FOR DEACTIVATING ACTIVATED STELLATE CELLS | ＩＳＭ株式会社 | 2023-11-23 | — | — | WO | claimed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | claimed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2025094914-A1 | TRANSPLANTATION DEVICE CAPABLE OF ENCAPSULATING CELLS THEREIN AND USE THEREOF | 株式会社VC Cell Therapy | 2025-05-08 | — | — | WO | disclosed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410962-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-116987667-A | Method for differentiating pluripotent stem cells into macrophages or neutrophils | 天海元祺生物科技(天津)有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | disclosed |
| CN-116731967-A | Method for preparing macrophage from multipotent stem cells by induced differentiation | 南京大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023054395-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | 住友ファーマ株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054396-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | 住友化学株式会社 | 2023-04-06 | — | — | WO | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022230977-A1 | CORD-LIKE AGGREGATES OF RETINAL PIGMENT EPITHELIAL CELLS, DEVICE AND PRODUCTION METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT COMPRISING SAID CORD-LIKE AGGREGATES | 国立研究開発法人理化学研究所 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | PRKCI 355/4885PRKCZ 369/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | PRKCI 1553/4885PRKCZ 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.